Nail psoriasis – what a rheumatologist should know about

Nieradko-Iwanicka, Barbara

doi:10.5114/reum.2017.66687

Cited by 5 publications

(2 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nails are skin appendages. If psoriasis involves the nail matrix, nail psoriasis shows up as changes in the nail plate such as pitting, Beau lines, leukonychia, red spots in the lunula, and nail plate crumbling [15]. Nail psoriasis is accompanied by onychomycosis in up to 27% of cases [14].…”

Section: Discussionmentioning

confidence: 99%

Deficiency of Interleukin-1 Receptor Antagonist: A Case with Late Onset Severe Inflammatory Arthritis, Nail Psoriasis with Onychomycosis and Well Responsive to Adalimumab Therapy

Kütükçüler

Puel

Akarcan

et al. 2019

Case Reports in Immunology

View full text Add to dashboard Cite

DIRA (deficiency of the IL-1Ra) is a rare condition that usually presents in the neonatal period. Patients with DIRA present with systemic inflammation, respiratory distress, joint swelling, pustular rash, multifocal osteomyelitis, and periostitis. Previously, we reported a patient with a novel mutation in IL1RN with a healthy neonatal period, a late-onset of pustular dermatosis, inflammatory arthritis, and excellent response to canakinumab treatment. Herein, we are presenting a new case of late-onset DIRA syndrome, carrying a different mutation and showing different clinical findings. This patient is the first one in the literature with the inflammatory arthritis, nail psoriasis, and onychomycosis and with her remarkable response to monoclonal antibodies. The case responded well and fully recovered after treatment with adalimumab, but not with canakinumab. The DIRA disease can lead to death from multiple organ failures and if recognized early, the treatment with replacement of the deficient protein with biologic agents induces rapid and complete remission. Therefore, clinical symptoms should be learned exactly by the pediatricians, pediatric rheumatologists, and immunologists; and molecular analysis targeting this defect must be performed as early as possible.

show abstract

Section: Discussionmentioning

confidence: 99%

Deficiency of Interleukin-1 Receptor Antagonist: A Case with Late Onset Severe Inflammatory Arthritis, Nail Psoriasis with Onychomycosis and Well Responsive to Adalimumab Therapy

Kütükçüler

Puel

Akarcan

et al. 2019

Case Reports in Immunology

View full text Add to dashboard Cite

show abstract

“…Psoriatic arthritis (PsA) is a heterogenous condition with musculoskeletal involvement, manifesting as a variety of symptoms including arthritis, dactylitis, enthesitis and axial involvement (Coates and Helliwell, 2017 ). In addition to musculoskeletal symptoms, patients with PsA have other symptoms such as nail disease, which affects between 63% and 83% of patients (Nieradko‐Iwanicka, 2017 ). Along with the varied nature of symptoms, the repercussions on patients are equally as diverse.…”

Section: Introductionmentioning

confidence: 99%

Outcome measures in psoriatic arthritis: Where next?

Hackett

Coates

2022

Musculoskeletal Care

View full text Add to dashboard Cite

Objective: To provide an overview of commonly used outcome measure in psoriatic arthritis (PsA).Background: PsA is a heterogenous inflammatory arthritis, associated with psoriasis that affects between 0.1% and 2% of the population and approximately one in three patients with psoriasis. Psoriatic arthritis places a significant burden on patients' overall quality of life and is associated with a range of comorbidities. Although assessment of patients and monitoring of symptoms has greatly improved over the last 2 decades, capturing disease activity in this multisystem disease remains challenging. Previous efforts have traditionally focussed on assessment of individual disease domains, however recent evidence suggests that composite measurements, particularly those incorporating patient reported outcomes may not only help monitor disease activity more accurately, but also help in accurately validating therapy outcomes in PsA patients.Purpose: This review discusses currently used outcome measurements in PsA and also highlights the importance of emerging measurements such as biomarkers and their possible role in capturing treatment response. K E Y W O R D S outcomes measurements, PROM, psoriatic arthritis 1 | INTRODUCTION Psoriatic arthritis (PsA) is a heterogenous condition with musculoskeletal involvement, manifesting as a variety of symptoms including arthritis, dactylitis, enthesitis and axial involvement (Coates and Helliwell, 2017). In addition to musculoskeletal symptoms, patients with PsA have other symptoms such as nail disease, which affects between 63% and 83% of patients (Nieradko-Iwanicka, 2017). Along with the varied nature of symptoms, the repercussions on patients are equally as diverse. Patients with PsA have an increased risk of comorbidities such as cardiovascular disease, metabolic syndromes, depression, inflammatory bowel disease and anxiety. In order to measure the impact of PsA on patients, a range of outcomes measures have been developed to ascertain disease impact and help monitor response to treatment in both clinical trials and the realworld settings. Despite the development of a range of outcome measures for patients, agreement as to the exact measure that should be utilized remains a challenge. Recent recommendations from the TIght Control Of Psoriatic Arthritis (TICOPA) trial have highlighted the need and importance of regular assessment of disease activity by clinicians, as well as the critical role patients play in capturing their own concerns (Coates et al., 2015). To capture these outcome measurements, The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)-Outcome Measures in Rheumatoid Arthritis Clinical Trials (OMERACT) PsA working group developed a This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

show abstract

Disease Modification in Psoriatic Arthritis

Lieberman

Ritchlin

2018

Curr Treat Options in Rheum

View full text Add to dashboard Cite

Nail psoriasis – what a rheumatologist should know about

Cited by 5 publications

References 24 publications

Deficiency of Interleukin-1 Receptor Antagonist: A Case with Late Onset Severe Inflammatory Arthritis, Nail Psoriasis with Onychomycosis and Well Responsive to Adalimumab Therapy

Deficiency of Interleukin-1 Receptor Antagonist: A Case with Late Onset Severe Inflammatory Arthritis, Nail Psoriasis with Onychomycosis and Well Responsive to Adalimumab Therapy

Outcome measures in psoriatic arthritis: Where next?

Disease Modification in Psoriatic Arthritis

Contact Info

Product

Resources

About